Corvus Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview

Corvus Pharmaceuticals

02/11/2024 04:06

* Corvus Pharmaceuticals Inc  CRVS.OQ   CRVS.O  is expected
to show no change in quarterly revenue when it reports 
results on November 5 (estimated) for the period ending
September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Corvus Pharmaceuticals
Inc is
for a loss of 11 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is 10.00​, above​ its last closing price
of $9.10. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -0.12       -0.11      -0.04     Beat    65.2
 Mar. 31 2024  -0.14                  -0.12             11.1
 Dec. 31 2023                         -0.14             -17.6​
 Sep. 30 2023  -0.12       -0.12      -0.12     Met     1.6
 ​​Jun.        -0.16       -0.14      -0.14     Met     -0.5
 30 2023                                                
 Mar. 31 2023  -0.16       -0.16      -0.17     Missed  -8.3​
 Jan. 1 0001   -0.25       -0.23      -0.21     Beat    9.1
 Sep. 30 2022  -0.16       -0.16      -0.32     Missed  -104.3
 This summary was machine generated November 2 at 04:05 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)